Published in Carcinogenesis on June 01, 2002
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
Mitochondria-mediated apoptosis by diallyl trisulfide in human prostate cancer cells is associated with generation of reactive oxygen species and regulated by Bax/Bak. Mol Cancer Ther (2007) 1.29
Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene (2009) 1.19
Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells. BMC Genomics (2008) 1.12
Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer (2005) 1.07
Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun (2015) 1.06
Bioinformatics approaches for cross-species liver cancer analysis based on microarray gene expression profiling. BMC Bioinformatics (2005) 1.04
3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol (2009) 1.02
RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res (2009) 0.94
Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis (2012) 0.92
The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol (2015) 0.91
Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer (2011) 0.91
Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet (2006) 0.90
Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br J Cancer (2013) 0.87
Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci (2014) 0.86
Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics (2007) 0.85
Transcriptome analysis of human gastric cancer. Mamm Genome (2005) 0.84
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. Proc Natl Acad Sci U S A (2015) 0.83
An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells. BMC Cancer (2007) 0.83
Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol (2012) 0.80
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells. BMC Biotechnol (2014) 0.80
Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer. J Biomed Biotechnol (2003) 0.80
TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins. Mol Endocrinol (2015) 0.79
Expression trend of selected ribosomal protein genes in nasopharyngeal carcinoma. Malays J Med Sci (2012) 0.79
KIBRA promotes prostate cancer cell proliferation and motility. FEBS J (2016) 0.79
Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells. Am J Cancer Res (2015) 0.78
Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using Limited Proteolysis. J Proteome Res (2016) 0.76
Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential. Horm Cancer (2016) 0.75
Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol (2017) 0.75
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget (2016) 0.75
Quantitative Assessment of Expression of Lactate Dehydrogenase and its Isoforms 3 and 4 may Serve as Useful Indicators of Progression of Gallbladder Cancer: A Pilot Study. Indian J Clin Biochem (2011) 0.75
Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells (2008) 2.93
The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev (2005) 2.70
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res (2004) 2.66
Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol (2006) 2.51
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res (2007) 2.00
Breast cancer survival of Hispanic women in the USA is influenced by country of origin. Asia Pac J Clin Oncol (2013) 1.99
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol (2010) 1.81
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res (2008) 1.77
Structure, evolution, and biology of the MUC4 mucin. FASEB J (2007) 1.75
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett (2013) 1.74
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 1.68
Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol (2010) 1.65
Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta (2006) 1.65
Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res (2007) 1.61
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol (2013) 1.58
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol (2008) 1.57
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol (2006) 1.55
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis (2005) 1.55
Epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells. J Biol Chem (2011) 1.52
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 1.50
MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol (2006) 1.48
Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res (2003) 1.47
Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev Biol (2010) 1.47
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol Reprod Dev (2009) 1.45
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells (2006) 1.40
Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells (2010) 1.40
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate (2006) 1.40
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res (2007) 1.37
Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev (2008) 1.36
Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev (2010) 1.33
Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci (2009) 1.31
Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release (2005) 1.31
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas (2003) 1.30
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer (2006) 1.26
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Neural invasion in the staging of pancreatic cancer. Pancreas (2003) 1.23
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer (2006) 1.22
Engineering antibodies for clinical applications. Trends Biotechnol (2007) 1.21
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta (2011) 1.20
RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses. Proc Natl Acad Sci U S A (2011) 1.19
Current status of mucins in the diagnosis and therapy of cancer. Biofactors (2009) 1.17
Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate (2007) 1.17
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther (2010) 1.16
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer (2003) 1.15
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther (2007) 1.15
Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine (2008) 1.15
Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One (2011) 1.14
MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res (2008) 1.13
Identification of novel domains within Sox-2 and Sox-11 involved in autoinhibition of DNA binding and partnership specificity. J Biol Chem (2003) 1.13
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol (2003) 1.13
Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene (2005) 1.13
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
What is the origin of pancreatic adenocarcinoma? Mol Cancer (2003) 1.11
Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol (2008) 1.11
Identification of DPPA4 and other genes as putative Sox2:Oct-3/4 target genes using a combination of in silico analysis and transcription-based assays. J Cell Physiol (2008) 1.11
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer (2005) 1.10
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res (2006) 1.10
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res (2004) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
Determination of protein interactome of transcription factor Sox2 in embryonic stem cells engineered for inducible expression of four reprogramming factors. J Biol Chem (2012) 1.10
MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One (2012) 1.09
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett (2010) 1.08
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
Taurocholate-induced pancreatitis: a model of severe necrotizing pancreatitis in mice. Pancreas (2008) 1.07
Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One (2012) 1.06
Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene. J Biol Chem (2004) 1.06
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett (2012) 1.06
Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol (2012) 1.06
RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells (2009) 1.05
High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer (2010) 1.05
Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm (2006) 1.05
Characterization of human mucin MUC17. Complete coding sequence and organization. J Biol Chem (2006) 1.04
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem (2010) 1.03
Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Anal Chem (2011) 1.03
Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 1.03